Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Erdheim-Chester disease].

Julien Haroche1, Zahir Amoura, Bertrand Wechsler

  • 1Service de médecine interne, Hôpital Pitié-Salpêtrière, Paris. julien.haroche@psl.aphp.fr

Presse Medicale (Paris, France : 1983)
|July 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL).

Rheumatology (Oxford, England)·2026
Same author

Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.

Haematologica·2026
Same author

Effect of a defatting pharmacologic cocktail with rapamycin during cold-to-warm ex situ perfusion of discarded human livers: A comparative study.

Surgery·2026
Same author

Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.

European journal of haematology·2026
Same author

Diagnostic Yield and Risks Associated With Retroperitoneal Biopsy in Erdheim-Chester Disease.

American journal of hematology·2026
Same author

ALK<sup>ATI</sup> Drives Nuclear Anaplastic Lymphoma Kinase (ALK) Expression in Histiocytic Neoplasms Without ALK Fusions.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Erdheim-Chester disease, a rare non-Langerhans cell histiocytosis, is increasingly diagnosed. Key diagnostic signs include bone scintigraphy and CT findings, with biopsy offering an elegant method.

Area of Science:

  • Pathology
  • Oncology

Context:

  • Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis.
  • While historically considered rare, ECD is diagnosed more frequently, with approximately 250 published cases.
  • Histiocytes in ECD are characterized by CD68 positivity and CD1a negativity, distinguishing it from Langerhans cell histiocytosis.

Purpose:

  • To highlight key diagnostic features of Erdheim-Chester disease.
  • To discuss the characteristic imaging findings and diagnostic methods for ECD.
  • To outline the significant clinical manifestations and prognostic factors associated with ECD.

Summary:

  • Characteristic imaging findings include consistent tracer uptake in long bones on technetium-99m bone scintigraphy and a "hairy kidney" appearance on abdominal CT scans.

Related Experiment Videos

  • Ultrasound-guided biopsy of perirenal infiltration provides an effective diagnostic approach.
  • Cardiovascular involvement, particularly aortic disease, and central nervous system infiltration, especially cerebellar, are severe complications impacting prognosis.

    • Impact:

    • Improved recognition of ECD's diagnostic markers can lead to earlier diagnosis.
    • Understanding cardiovascular and CNS involvement is crucial for managing patient prognosis.
    • Early diagnosis and tailored treatment strategies, potentially starting with interferon alfa, can improve outcomes for Erdheim-Chester disease patients.